文献
J-GLOBAL ID:201702237267447243
整理番号:17A1098159
継電器研究のための治療理論的根拠と研究設計:多施設,無作為化,上皮成長因子受容体変異陽性転移性肺非小細胞癌患者のラムシルマブまたはプラセボを用いたエルロチニブの二重盲検試験【Powered by NICT】
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer
著者 (13件):
Garon Edward B.
(David Geffen School of Medicine at UCLA, Los Angeles, CA)
,
Reck Martin
(Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany)
,
Paz-Ares Luis
(Hospital Doce de Octubre, Madrid, Spain)
,
Ponce Santiago
(Hospital Doce de Octubre, Madrid, Spain)
,
Jaime Jesus Corral
(Hospital Virgen del Rocio, Sevilla, Spain)
,
Juan Oscar
(Hospital Universitario La Fe, Valencia, Spain)
,
Nadal Ernest
(Institut Catala d’Oncologia, L’Hospitalet, Barcelona, Spain)
,
Lee Pablo
(Eli Lilly and Company, Bridgewater, NJ)
,
Dalal Rita
(Eli Lilly and Company, Bridgewater, NJ)
,
Liu Jingyi
(Eli Lilly and Company, Indianapolis, IN)
,
He Shuang
(Eli Lilly and Company, Indianapolis, IN)
,
Treat Joseph
(Eli Lilly and Company, Indianapolis, IN)
,
Nakagawa Kazuhiko
(Kinki University School of Medicine, Osaka, Japan)
資料名:
Clinical Lung Cancer
(Clinical Lung Cancer)
巻:
18
号:
1
ページ:
96-99
発行年:
2017年
JST資料番号:
W3210A
ISSN:
1525-7304
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)